Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography

Liver International

Volumn 32, Issue 6, 2012, Pages 911-918

  de Lédinghen, Victor ^a,b   Vergniol, Julien ^a   Foucher, Juliette ^a   Merrouche, Wassil ^a   le Bail, Brigitte ^a,b,c  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

Fibrosis; Liver stiffness measurement; Metabolic syndrome; NAFLD; NASH; Non invasive markers

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOACCUMULATION; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CELL NUCLEUS; CHRONIC LIVER DISEASE; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER; FEMALE; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LIVER BIOPSY; LIVER CELL; LIVER EXAMINATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INVASIVE MEASUREMENT; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; WAIST CIRCUMFERENCE;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; CHRONIC DISEASE; CLINICAL ENZYME TESTS; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; FRANCE; HUMANS; LINEAR MODELS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84861981022     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02820.x     Document Type: Article

References (34)

1. Bedogni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
2. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
3. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
4. Weston SR, Leyden W, Murphy R et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-9.
5. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24: 399-413.
6. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
7. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
8. Poynard T, Ratziu V, Naveau S et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10.
9. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
10. Schwenzer NF, Springer F, Schraml C et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-45.
11. Sasso M, Beaugrand M, de Ledinghen V et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35.
12. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
13. de Ledinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010; 7: 811-23.
14. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
15. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
16. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-96.
17. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15: 246-58.
18. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
19. Obuchowski NA. An ROC-type measure of diagnostic accuracy when the gold standard is continuous-scale. Stat Med 2006; 25: 481-93.
20. Lambert J, Halfon P, Penaranda G et al. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008; 54: 1372-8.
21. Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
22. Fan JG, Zhu J, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-14.
23. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
24. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.
25. Roldan-Valadez E, Favila R, Martinez-Lopez M, Uribe M, Mendez-Sanchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 2008; 7: 212-20.
26. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
27. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90.
28. Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14: 3476-83.
29. McPherson S, Jonsson JR, Cowin GJ et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol 2009; 51: 389-97.
30. Guiu B, Loffroy R, Hillon P, Petit JM. Magnetic resonance imaging and spectroscopy for quantification of hepatic steatosis: urgent need for standardization! J Hepatol 2009; 51: 1082-3; author reply 1083-4.
31. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
32. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
33. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
34. Gawrieh S, Knoedler DM, Saeian K, Wallace JR, Komorowski RA. Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Pathol 2011; 15: 19-24.